Critical Care · 2015 · 62 citations · 34 references
MedicineNeurologyPharmacotherapyClinical EpidemiologyNeurologic PharmacotherapyStroke RehabilitationAcute Ischemic StrokeAcute Stroke ManagementCerebrovascular DiseaseNeuroprotectionStrokeStroke PharmacotherapyAcute Ischemic Stroke ManagementAcute Ischemic Stroke TreatmentLong-term Neurologic OutcomesLong-term Neurological SequelaeNeurological DeteriorationNeurological DisabilityPlacebo-controlled Efficacy AssessmentStroke Severity Assessment
INTRODUCTION: Mortality and disability following ischemic stroke (IS) remains unacceptably high with respect to the conventional therapies. This study tested the effect of erythropoietin (EPO) on long-term neurological outcome in patients after acute IS. This study aimed to evaluate the safety and efficacy of two consecutive doses of EPO (5,000 IU/dose, subcutaneously administered at 48 hours and 72 hours after acute IS) on improving the 90-day combined endpoint of recurrent stroke or death that has been previously reported. A secondary objective was to evaluate the long-term (that is, five years) outcome of patients who received EPO. METHODS: This was a prospective, randomized, placebo-controlled trial that was conducted between October 2008 and March 2010 in a tertiary referral center. IS stroke patients who were eligible for EPO therapy were enrolled into the study. RESULTS: The results showed that long-term recurrent stroke and mortality did not differ between group 1 (placebo-control; n = 71) and group 2 (EPO-treated; n = 71). Long-term Barthel index of <35 (defining a severe neurological deficit) was lower in group 2 than group 1 (P = 0.007). Multiple-stepwise logistic-regression analysis showed that EPO therapy was significantly and independently predictive of freedom from a Barthel index of <35 (P = 0.029). Long-term major adverse neurological event (MANE; defined as: death, recurrent stroke, or long-term Barthel index < 35) was lower in group 2 than group 1 (P = 0.04). Log-Rank test showed that MANE-free rate was higher in group 2 than group 1 (P = 0.031). Multiple-stepwise Cox-regression analysis showed that EPO therapy and higher Barthel Index at day 90 were independently predictive of freedom from long-term MANE (all P <0.04). CONCLUSION: EPO therapy significantly improved long-term neurological outcomes in patients after IS. TRIAL REGISTRATION: ISRCTN71371114 . Registered 10 October 2008.
34
Functional evaluation : Barthel index
F. I. Mahonery · Medical Entomology and Zoology · 1965 · 12.9K citations
Harold P. Adams, Birgitte H. Bendixen, L. Jaap Kappelle et al. · Stroke · 1993 · 12.3K citations · Full text
FUNCTIONAL EVALUATION: THE BARTHEL INDEX.
Florence Mahoney, DOROTHEA W. BARTHEL · PubMed · 1965 · 5.9K citations
Isolated Hand Paresis: A Case Series
Karl Bjørnar Alstadhaug, Ane Skaare Sjulstad · Cerebrovascular Diseases Extra · 2013 · 4.1K citations · Full text
Medicine, Anatomy, Neuroscience +15